These findings suggest an important role for U2AF35 in the physiological maintenance and function of HSPC during hematopoiesis and highlight potential downstream effectors of the U2AF1-mutant phenotype which might represent therapeutic targets for hematologic malignancies. The gene discussed is U2AF1; the disease is hematologic disorder.